The Advanced Addiction Psychopharmacology Course is Going Virtual!

Saturday, November 7, 2020 and Saturday, November 14, 2020. *Registration is closed.

Course Schedule

Information for Registrants

  • A CrowdCompass account is required to access the course content and to gain access to the live webinar Q&A sessions. Please check your email for instructions on how to download CrowdCompass.
  • All of the course content (including access to the on-demand presentations) will be available to course registrants until June 30, 2021.
  • We do plan to record the live Q&A sessions and make them available to course registrants in mid-October. Registrants will receive an email notification when they become available in your CrowdCompass account.
  • After the live webinar sessions conclude on November 14th, verified course participants will be sent an email (to the email address you registered with) that contains a link to an evaluation survey. Completing the survey is how course registrants will obtain their CE credit certificates.

View Presenter Financial Disclosure Information

Who Should Attend?

This intensive, 12-hour, online course is designed for physicians and other health care professionals who have a foundation in prescribing medication for patients with substance use disorders, including those with co-occurring psychiatric conditions, but would like a deeper understanding of these pharmacotherapies. The Advanced Addiction Psychopharmacology Course will consist of two complementary components, including 9 on-demand video presentations, followed by a 2-day series of live webinar case discussions and Q&A sessions held on Saturday, November 7th from 12:00pm – 3:35pm ET and Saturday, November 14th from 12:00pm – 4:00pm ET. Course participants can earn up to 12 AMA PRA Category 1 Credits™.

View Continuing Education Credits

Educational Objectives

This course is designed for learners with a foundational knowledge of addiction psychiatry will who wish to receive a more in-depth educational training in addiction psychopharmacology.

After participating in this course, learners should be able to:

  • Describe how to use methadone, buprenorphine and naltrexone in clinical practice for the treatment of opioid use disorders.
  • Describe medication treatments for alcohol use disorders.
  • Determine when to use varenicline, bupropion, and nicotine replacement therapy (NRT) for treatment of nicotine use disorder.
  • Discuss new evidence-based medication treatments for cocaine and methamphetamine use disorder.
  • Discuss new evidence-based medication treatments for cannabis use disorder.
  • Discuss medication approaches for the treatment of sedative-hypnotic use disorder.
  • List evidence-based options for anti-depressant and anti-anxiety pharmacotherapy when treating patients with a co-occurring substance use disorder.
  • Discuss evidence-based pharmacotherapy for treatment of ADHD with co-occurring substance use disorders.
  • Discuss the pharmacotherapy of bipolar disorder in patients with co-occurring substance use disorder.